Dotarizin

Из Википедије, слободне енциклопедије
Dotarizin
(IUPAC) ime
1-[difenilmetil]-4-[3-(2-fenil-1,3-dioksolan-2-il)propil]piperazin
Klinički podaci
Identifikatori
CAS broj 84625-59-2
ATC kod nije dodeljen
PubChem[1][2] 55285
UNII IO7663S6D3 YesY
Hemijski podaci
Formula C29H34N2O2 
Mol. masa 442,592 g/mol
SMILES eMolekuli & PubHem
Sinonimi Dotarizine
Farmakoinformacioni podaci
Trudnoća  ?
Pravni status

Dotarizin je lek koji se koristi za tretman migrene.[3] On deluje kao blokator kalcijumovog kanala,[4] antagonist 5HT2A receptora, i u manjoj meri 5HT1A i 5HT2C receptora.[5][6] On ima antimigrenski efekat jer deluje kao vazodilatator,[7][8] i zato što ima izvesno anksiolitičko dejstvo.[9] Dotarizin blokira amneziju proizvedenu elektrokonvulzivnim šokom kod životinja.[10]

Reference[уреди]

  1. Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.“. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519.  edit
  2. Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities“. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1. 
  3. Ruiz-Nuño, A; Villarroya, M; Cano-Abad, M; Rosado, A; Balfagón, G; López, MG; García, AG (2001). „Mechanisms of blockade by the novel migraine prophylactic agent, dotarizine, of various brain and peripheral vessel contractility“. European Journal of Pharmacology 411 (3): 289–99. DOI:10.1016/S0014-2999(00)00897-9. PMID 11164387. 
  4. Ruiz-Nuño, A; Mayorgas, I; Hernández-Guijo, JM; Olivares, R; García, AG; Gandía, L (2003). „Antimigraine dotarizine blocks P/Q Ca2+ channels and exocytosis in a voltage-dependent manner in chromaffin cells“. European Journal of Pharmacology 481 (1): 41–50. DOI:10.1016/j.ejphar.2003.09.013. PMID 14637173. 
  5. Farré, M; Roset, PN; Llorente, M; Márquez, M; Albet, C; Pérez, JA; Herrero, E; Ortíz, JA (1997). „Clinical pharmacokinetics and tolerability of dotarizine in healthy subjects after single and multiple oral administration“. Methods and findings in experimental and clinical pharmacology 19 (5): 343–50. PMID 9379783. 
  6. Montiel, C; Herrero, CJ; García-Palomero, E; Renart, J; García, AG; Lomax, RB (1997). „Serotonergic effects of dotarizine in coronary artery and in oocytes expressing 5-HT2 receptors“. European Journal of Pharmacology 332 (2): 183–93. DOI:10.1016/S0014-2999(97)01073-X. PMID 9286620. 
  7. Kuridze, N; Gajkowska, B; Czernicki, Z; Jurkiewicz, J; Cervos-Navarro, J (1998). „The effect of Dotarizine--(Ca2+ channel blocker)--on vascular reactivity and ultrastructure of cerebral capillaries in animals subjected to anoxia“. Folia neuropathologica / Association of Polish Neuropathologists and Medical Research Centre, Polish Academy of Sciences 36 (2): 101–8. PMID 9757621. 
  8. Kuridze, N; Czernicki, Z; Jarus-Dziedzic, K; Jurkiewicz, J; Cervos-Navarro, J (2000). „Regional differences of cerebrovascular reactivity effected by calcium channel blocker - dotarizine“. Journal of the neurological sciences 175 (1): 13–6. DOI:10.1016/S0022-510X(00)00275-6. PMID 10785251. 
  9. Petkov, VD; Belcheva, S; Konstantinova, E (1995). „Anxiolytic effects of dotarizine, a possible antimigraine drug“. Methods and findings in experimental and clinical pharmacology 17 (10): 659–68. PMID 9053586. 
  10. Lazarova, M; Petkova, B; Petkov, VD (1995). „Effect of dotarizine on electroconvulsive shock or pentylenetetrazol-induced amnesia and on seizure reactivity in rats“. Methods and findings in experimental and clinical pharmacology 17 (1): 53–8. PMID 7623521. 

Spoljašnje veze[уреди]